Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of RO7890597 in Healthy Adult Volunteers
Sponsor: Genentech, Inc.
Summary
This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers. The study includes single ascending dose (SAD) stage, multiple ascending dose (MAD) stage, food-effect and proton pump inhibitor (PPI) stages, and a supplemental drug-drug interaction (DDI) stage.
Official title: A Phase I Study to Evaluate the Safety and Pharmacokinetics of RO7890597 Following Single and Multiple Ascending Doses, and the Effects of Food, Proton-Pump Inhibition, And CYP3A Inhibition in Healthy Adult Volunteers
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
139
Start Date
2026-08-28
Completion Date
2027-06-08
Last Updated
2026-09-01
Healthy Volunteers
Yes
Conditions
Interventions
RO7890597
Participants will receive RO7890597 as per the schedule described in the protocol.
Placebo
Participants will receive matching placebo as per the schedule described in the protocol.
Rabeprazole
Participants will receive rabeprazole as per the schedule described in the protocol.
Itraconazole
Participants will receive itraconazole as per the schedule described in the protocol.
Locations (1)
ICON (LPRA) - Lenexa
Lenexa, Kansas, United States